SEC Form 4 · accession 0001213900-17-012293
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John K Bell
Director
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Nov 15, 2017 | P | 1,871 | $0.81 | A | 76,890 | I | See footnote |
| Common StockF2,F3 | Nov 16, 2017 | P | 18,129 | $0.81 | A | 95,019 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $0.7997 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $0.8086 to $0.81. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Shares are held by Onbelay Capital Inc.